Navigation Links
AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
Date:10/24/2008

QUEBEC CITY, Oct. 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it received a letter from the Nasdaq Stock Market, notifying AEterna Zentaris that during the 30 consecutive business days prior to October 16, 2008, the bid price of the Company's common shares had closed below the US$1.00 minimum bid per share required for continued inclusion on the Nasdaq Global Market under Marketplace Rule 4450(a)(5). However, the letter states that given the current extraordinary market conditions, Nasdaq has determined to suspend enforcement of the bid price and market value of publicly held shares requirements through Friday, January 16, 2009. In that regard, the letter states that on October 16, 2008, Nasdaq filed an immediately effective rule change with the Securities and Exchange Commission to implement the suspension. According to Nasdaq, these rules will be reinstated on Monday, January 19, 2009 and the first relevant trade date will be Tuesday, January 20, 2009.

Therefore, following the reinstatement of these rules, and in accordance with Marketplace Rule 4450(e)(2), AEterna Zentaris will be provided 180 calendar days from Tuesday, January 20, 2009, or until July 20, 2009, to regain compliance with the US$1.00 minimum bid per share under Marketplace Rule 4450(a)(5). If, at any time before July 20, 2009, including during the suspension period, the bid price of the Company's common shares closes at US$1.00 per share or more for a minimum of 10 consecutive business days, Nasdaq will provide written notification that AEterna Zentaris has achieved compliance with Marketplace Rule 4450(a)(5).

If the Company is
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
3. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
4. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
5. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
6. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
7. AEterna Zentaris Sells Quebec City Building for $7.1 million
8. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
9. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
10. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
11. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... be allowed to tax Internet usage, in a move that ... hole in the state budget. , ,The federal measure to ... , R-Wis., who said home users could save around a ... Tax Nondiscrimination Act, a tech-neutral plan that exempts all Internet ...
... Dark Ages, where marks were burned onto cattle. On ever-so-slowly-evolving minds ... solid impression and provides a daily dose of comfort. Belonging to ... a security blanket. A warm fuzzy feeling when a huge name ... craves to carry something with a logo, color and stripes, wear ...
... Wis. The North Carolina simulated learning company ... the Croquet Project at UW-Madison, a graphical communications ... trade show in Orlando that it has begun developing software ... applied to military and commercial avenues. , ,What were doing ...
Cached Biology Technology:State faces revenue drop as federal Internet tax ban passes House 2The black hole of corporate branding 2The black hole of corporate branding 3The black hole of corporate branding 4UW open-source 3D environment tapped for commercial development 2
(Date:8/20/2014)... therapy developed by researchers at the University of Missouri ... from a life-threatening heart condition caused by muscular dystrophy. ... Yi Lai, Ph.D., the leading author of the study ... Medicine,s Department of Molecular Microbiology and Immunology. "This is ... lead to a treatment for people with this devastating ...
(Date:8/20/2014)... 1 (PS1) absorbs light and its energy is ... to biomass. Photovoltaic devices, mostly build from silicon ... electricity. One approach for the development of cheaper ... with the isolated membrane protein complexes of photosynthesis. ... stable PS1 from thermophilic cyanobacteria that live in ...
(Date:8/19/2014)... to decrease China,s increasing caesarean section rate, suggests a ... An International Journal of Obstetrics and Gynaecology (BJOG) . ... rates in the world. Of 16 million babies born ... exact rate is not known, the current Chinese language ... rates ranging from 36% to 58%. However, before the ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2A semi-artificial leaf faster than 'natural' photosynthesis 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3
... urine test for prostate cancer that measures minute fragments ... through the University of Michigan MLabs. The new testMi-Prostate ... increases physicians, ability to pick out high-risk prostate tumors ... of thousands of men avoid unnecessary biopsies. The ...
... 2013 MedNet Solutions , a global life ... is pleased to announce that Accelovance , an ... phase Oncology, Vaccines and General Medicine development, has joined ... .    Designation as an iMedNet Partner will ...
... the first ever interior 3D map of Italy,s iconic Leaning ... system. Developed by the CSIRO, Australia,s national science agency, ... a laser scanner that sways on a spring to capture ... an operator can walk through it. Specialised software then converts ...
Cached Biology News:Prostate Cancer Foundation announces new urine test for prostate cancer available 2Prostate Cancer Foundation announces new urine test for prostate cancer available 3MedNet Solutions Proudly Welcomes Accelovance To The iMedNet Partner Program 2MedNet Solutions Proudly Welcomes Accelovance To The iMedNet Partner Program 33D mapping is a 'Pisa' cake for Aussie scientists 2
... software, PC, is used to perform ... obtained from the Experion automated electrophoresis ... electropherogram and simulated gel views and ... in a Results table. This software ...
... use in the Microsart e.motion are sterile-sealed, without ... a specially designed individual package on a band. ... of membrane filter units ensures that they are ... sealed band guarantees uniform dispensing of the individual ...
... that will help protect your PCR runs ... work area prior to use, reducing the ... Containment features reduce the chance of airborne ... for a clear view, an acid-resistant black ...
...
Biology Products: